| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3990860 | Journal of Thoracic Oncology | 2012 | 7 Pages |
Abstract
We observed no significant differences in OS and PFS between patients receiving erlotinib, docetaxel, and pemetrexed. Nevertheless, erlotinib and docetaxel were associated with a statistically significant lower costs and resource use relative to pemetrexed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Eric MD, Michael RPh, MBA, Sacha PhD, Carolina PhD,